Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Posted by on May 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...

Read More

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More

Searching for patients with advanced prostate cancer to trial an immunotherapy

Searching for patients with advanced prostate cancer to trial an immunotherapy

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...

Read More

Can physical exercise improve the quality of life of patients with prostate cancer?

Can physical exercise improve the quality of life of patients with prostate cancer?

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of physical exercise in patients with prostate cancer. The study concluded that physical exercise is associated with reduction of tiredness, and improving functional capacity and quality of life in these patients. Some background Prostate cancer (PCa) is the second most common form of...

Read More

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

Posted by on Apr 25, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes and effectiveness of administering additional (adjuvant) androgen deprivation therapy (A-ADT) for long-term after radiotherapy (RT) in high-risk or very high-risk locally advanced prostate cancer (LAPC). The study found that the addition of A-ADT longer than 1 year after RT showed good treatment outcomes...

Read More

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Apr 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of lutetium-177 [177Lu]-PSMA-617 (177LuPSMA) versus cabazitaxel (Jevtana) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 177LuPSMA treatment showed a higher response with fewer side effects in these patients. Some...

Read More

Comparing the safety outcomes between proton beam therapy vs intensity-modulated radiation therapy in early stage prostate cancer

Comparing the safety outcomes between proton beam therapy vs intensity-modulated radiation therapy in early stage prostate cancer

Posted by on Mar 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the safety outcomes between moderately-hypofractionated intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) in patients with early-stage prostate cancer. The data showed that both treatments were safe and well-tolerated. Some background Radiation therapy (RT) is a treatment used for low- or...

Read More

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Posted by on Mar 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...

Read More

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients with prostate cancer with lower urinary tract symptoms (LUTS) during active surveillance. The results suggested that PVP treatment was safe and effective in these patients. Some background Active surveillance (AS)...

Read More